#BPROAD

HTN in Diabetics

#BPROAD trial showed that in patients with type 2 DM & HTN with elevated CV risk, intensive treatment targeting SBP ≤120 mm Hg reduced the incidence of MACE at 5 years compared with standard treatment targeting ≤140 mm Hg.
(SPRINT Trial was in Nondiabetics)

Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | NEJM Effective targets for systolic blood-pressure control in patients with type 2 diabetes are unclear. We enrolled patients 50 years of age or older with type 2 diabetes, elevated systolic blood press...

➡️ Up next on #NephJC #NephSky 🦋

Join us for some high pressure discussion on Dec 3,4 as we discuss #BPROAD from #NEJM

nejm.org/doi/abs/10.1...

Tweetorial by @drpallaviprasad.bsky.social

#BPROAD Graphical abstract #AHA24

Very low kidney risk enrolled in #BPROAD

Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
#BPROAD

www.nejm.org/doi/full/10....
#NEJM #AHA24 #CardioSky #Hypertension #MedSky
@ahascience.bsky.social @dramitkhera.bsky.social

Dr. Guang Ning presents on the effect of intensive BP lowering in Diabetes
#AHA24 #BPROAD study
🫀intensive 🆚 UC: <120 🆚 <140 SBP🎯
🫀12,821 patients enrolled
🫀45% 💃🏻 mean age 63
💥21% reduction in CV events in intensive tx ! SAE same
📎 www.nejm.org/doi/full/10....